Alzheimer’s disease is the most common cause of dementia in older adults. It slowly damages the brain and leads to memory loss, confusion, and difficulty thinking.
Over time, people with Alzheimer’s may struggle with everyday activities such as remembering names, managing money, or recognizing familiar places. As the global population ages, Alzheimer’s disease has become one of the biggest health challenges facing families and healthcare systems around the world.
In recent years, scientists have developed new medicines designed to slow the progression of Alzheimer’s disease. These treatments target a substance in the brain called amyloid.
Amyloid forms sticky clumps, known as plaques, that build up between brain cells and are believed to play an important role in the development of Alzheimer’s disease. The new treatments use special laboratory-made antibodies that attach to amyloid and help remove it from the brain.
Two of the newest drugs in this category are lecanemab and donanemab. These medications are known as anti-amyloid monoclonal antibodies. Clinical trials have shown that they can modestly slow the worsening of memory and thinking problems in some patients with early Alzheimer’s disease.
Because of these results, many doctors and patients are hopeful that these drugs represent an important step forward in Alzheimer’s treatment.
However, these new therapies also come with risks. One of the most important concerns is a condition called amyloid-related imaging abnormalities, often shortened to ARIA. Doctors detect ARIA using brain scans such as MRI.
In some cases, ARIA reflects swelling in the brain, while in other cases it can indicate small areas of bleeding. Although many people with ARIA do not develop symptoms, the condition can sometimes become serious.
Because of the possibility of bleeding in the brain, doctors are usually cautious about giving certain other medications to patients receiving anti-amyloid therapy.
In particular, medications that thin the blood or dissolve blood clots may increase the risk of bleeding. These drugs are known as anticoagulants and thrombolytics. They are commonly prescribed to treat or prevent heart attacks, strokes, and other cardiovascular conditions.
A new study has now highlighted an important challenge for doctors and families considering anti-amyloid treatments. The research shows that many older adults with mild cognitive impairment or dementia develop new heart or blood vessel conditions each year that may require these blood-thinning medications.
The study was published in the medical journal Neurology. It was led by Dr. Dae Hyun Kim, a senior scientist at the Hinda and Arthur Marcus Institute for Aging Research at Hebrew SeniorLife. The research team analyzed information from the Health and Retirement Study, a large national study that follows the health and aging of Americans over time.
The researchers examined data from 12,373 adults aged 65 and older between 2010 and 2020. At the start of the study, none of the participants had conditions that required treatment with anticoagulants or clot-dissolving drugs. This allowed the researchers to observe how often these medical conditions developed later.
Participants were divided into three groups based on their level of cognitive health. Some participants had normal thinking and memory.
Others had mild cognitive impairment, a condition in which people have noticeable memory problems but can still function independently. The third group included individuals with dementia, whose thinking and memory problems significantly affected daily life.
The researchers then looked at how many people developed new cardiovascular conditions within one year. These conditions included atrial fibrillation, which is an irregular heartbeat that increases stroke risk, deep vein thrombosis, which is a dangerous blood clot in the leg, pulmonary embolism, which is a clot in the lungs, heart attacks, and strokes.
The results showed that these conditions were not uncommon among people with cognitive problems. Among participants with mild cognitive impairment, about 5.7 percent developed a new medical condition within one year that could require treatment with blood-thinning or clot-dissolving drugs.
Among people with dementia, the number was even higher, with about 6.7 percent developing such conditions within a year.
These findings reveal an important issue for doctors treating Alzheimer’s disease. Anti-amyloid therapies may help slow cognitive decline, but they are generally not recommended for people who are taking anticoagulants or thrombolytic medications because of the increased risk of bleeding in the brain.
If a patient develops a heart condition that requires blood thinners while receiving anti-amyloid treatment, doctors may need to reconsider the treatment plan.
The study therefore highlights a potential “medical collision” between two different types of treatment. On one hand, anti-amyloid therapies may help slow the progression of Alzheimer’s disease. On the other hand, cardiovascular conditions are very common in older adults and often require medications that increase bleeding risk.
Dr. Kim explained that the study provides valuable real-world information about how often these situations occur. Understanding these risks can help doctors, patients, and families make more informed decisions when considering anti-amyloid therapy.
The findings also reflect a broader reality about aging and health. Many older adults live with several medical conditions at the same time. A treatment that benefits one disease may sometimes create complications for another condition.
This makes medical decision-making more complex, especially for patients with dementia who may already face many health challenges.
Overall, the study does not suggest that anti-amyloid therapies should be avoided. Instead, it highlights the importance of careful evaluation before starting treatment. Doctors may need to review a patient’s heart health, stroke risk, and overall medical history when deciding whether these new Alzheimer’s treatments are appropriate.
From a broader perspective, the findings also remind researchers and clinicians that Alzheimer’s disease does not occur in isolation.
Many patients with cognitive impairment are also dealing with cardiovascular disease, which is one of the leading causes of illness and death in older adults. Future research may need to explore ways to safely combine treatments for both brain and heart conditions.
The results of this study are important because they provide real-world estimates of how often these treatment conflicts may occur. By understanding the likelihood of new heart-related conditions in people with cognitive impairment, doctors and families can better weigh the potential benefits and risks of new Alzheimer’s therapies.
In summary, the study highlights an important challenge in modern Alzheimer’s care. While new anti-amyloid treatments offer hope for slowing memory decline, many patients may later develop cardiovascular conditions that require medications incompatible with these therapies.
Careful medical assessment and shared decision-making will therefore be essential when considering these new treatments for patients with Alzheimer’s disease.
If you care about Alzheimer’s, please read studies about the likely cause of Alzheimer’s disease , and new non-drug treatment that could help prevent Alzheimer’s.
For more health information, please see recent studies about diet that may help prevent Alzheimer’s, and results showing some dementia cases could be prevented by changing these 12 things.
The research findings can be found in Neurology.
Copyright © 2026 Knowridge Science Report. All rights reserved.
